Centennial Wealth Advisory LLC Purchases 83 Shares of Amgen Inc. (NASDAQ:AMGN)

Centennial Wealth Advisory LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,347 shares of the medical research company’s stock after acquiring an additional 83 shares during the period. Centennial Wealth Advisory LLC’s holdings in Amgen were worth $351,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the third quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new stake in Amgen in the third quarter worth about $29,000. Matrix Trust Co purchased a new stake in Amgen in the third quarter worth about $36,000. Heck Capital Advisors LLC purchased a new stake in Amgen in the fourth quarter worth about $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen in the third quarter worth about $56,000. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. UBS Group lowered their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Piper Sandler lowered their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. TD Cowen increased their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Bank of America reissued an “underperform” rating and set a $256.00 price target on shares of Amgen in a research report on Tuesday, December 10th. Finally, Piper Sandler Companies reissued an “overweight” rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $314.00.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $307.81 on Thursday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company’s 50 day moving average is $271.14 and its 200 day moving average is $303.52. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market cap of $165.46 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. On average, sell-side analysts forecast that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.